{
    "organizations": [],
    "uuid": "19510c72cabbce697dcc9bbb827437609367b3e0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-luye-pharma-updates-on-development/brief-luye-pharma-updates-on-development-of-ansofaxine-hydrochloride-extended-release-tablets-idUSFWN1PI0OU",
    "ord_in_thread": 0,
    "title": "BRIEF-Luye Pharma ‍Updates On Development Of Ansofaxine Hydrochloride Extended Release Tablets​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 23 (Reuters) - Luye Pharma Group Ltd:\n* ‍UPDATES ON PHASE II CLINICAL TRIAL IN CHINA FOR ANSOFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS​\n* PRELIMINARY RESULTS OF PHASE II TRIAL MET PRIMARY EFFICACY ENDPOINT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-23T21:12:00.000+02:00",
    "crawled": "2018-01-24T15:27:46.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "luye",
        "pharma",
        "group",
        "ltd",
        "phase",
        "ii",
        "clinical",
        "trial",
        "china",
        "ansofaxine",
        "hydrochloride",
        "extended",
        "release",
        "preliminary",
        "result",
        "phase",
        "ii",
        "trial",
        "met",
        "primary",
        "efficacy",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}